Voyager Therapeutics (VYGR) Long-Term Investments (2015 - 2026)

Voyager Therapeutics has disclosed Long-Term Investments across 12 years of filings, most recently posting $30.2 million for Q1 2026.

• Long-Term Investments for Q1 2026 came in at $30.2 million, down 48.93% year-over-year; the trailing twelve-month figure through Mar 2026 was $30.2 million (down 48.93% YoY), and the FY2025 annual result was $5.2 million, down 92.02% from the prior year.
• Long-Term Investments came in at $30.2 million for Q1 2026 at Voyager Therapeutics, up from $5.2 million in the prior quarter.
• In the past five years, Long-Term Investments ranged from a high of $65.7 million in Q4 2024 to a low of $1.0 million in Q1 2024.
• The 5-year median for Long-Term Investments is $1.8 million (2022), against an average of $14.5 million.
• Peak annual rise in Long-Term Investments reached 5810.3% in 2025, while the deepest fall reached 92.02% in 2025.
• Voyager Therapeutics' Long-Term Investments stood at $1.5 million in 2022, then climbed by 5.15% to $1.6 million in 2023, then soared by 4024.54% to $65.7 million in 2024, then slumped by 92.02% to $5.2 million in 2025, then surged by 475.53% to $30.2 million in 2026.
• The last three Long-Term Investments figures came in at $30.2 million (Q1 2026), $5.2 million (Q4 2025), and $20.1 million (Q3 2025), per Business Quant data.